Cladribine and Ocrelizumab induce differentially modulated microRNA profiles in mononucleated blood cells from relapsing-remitting Multiple Sclerosis patients

被引：0
|
作者：
Arisi, Ivan [1 ]
Malimpensa, Leonardo [2 ]
Manzini, Valeria [2 ]
Brandi, Rossella [3 ]
D'Amelio, Chiara [4 ]
di Sturmeck, Tommaso Gosetti [1 ]
Crisafulli, Sebastiano [5 ]
Ferrazzano, Gina [2 ]
Belvisi, Daniele [2 ]
Malerba, Francesca [1 ]
Florio, Rita [1 ]
Pascale, Esterina [2 ]
Soreq, Hermona [6 ,7 ]
Salvetti, Marco [2 ]
Cattaneo, Antonino [1 ]
D'Onofrio, Mara [1 ]
Conte, Antonella [2 ]
机构：
[1] EBRI, European Brain Res Inst Rita Levi Montalcini, Rome, Italy
[2] Univ Roma La Sapienza, Rome, Italy
[3] Sci Dept Army Med Ctr, Rome, Italy
[4] Univ Cattolica Sacro Cuore, Rome, Italy
[5] Multiple Sclerosis Ctr, Milan, Italy
[6] Hebrew Univ Jersusalem, Edmond & Lily Safra Ctr Brain Sci, Jerusalem, Israel
[7] Hebrew Univ Jersusalem, Inst Life Sci, Jerusalem, Israel
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1415/1877
引用
收藏
页码：902 / 902
页数：1
相关论文
共 50 条
  • [1] Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients
    Arisi, Ivan
    Malimpensa, Leonardo
    Manzini, Valeria
    Brandi, Rossella
    di Sturmeck, Tommaso Gosetti
    D'Amelio, Chiara
    Crisafulli, Sebastiano
    Ferrazzano, Gina
    Belvisi, Daniele
    Malerba, Francesca
    Florio, Rita
    Pascale, Esterina
    Soreq, Hermona
    Salvetti, Marco
    Cattaneo, Antonino
    D'Onofrio, Mara
    Conte, Antonella
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [3] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [4] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
  • [5] Cladribine TabletsIn Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2011, 25 : 239 - 249
  • [6] Cladribine Tablets In Relapsing-Remitting Multiple Sclerosis
    Muir, Victoria J.
    Plosker, Greg L.
    CNS DRUGS, 2011, 25 (03) : 239 - 249
  • [7] An update on cladribine for relapsing-remitting multiple sclerosis
    Holmoy, Trygve
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1627 - 1635
  • [8] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1163 - 1175
  • [9] Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis
    Hodgkinson, S.
    Lizak, N.
    Butler, E.
    Lechner-Scott, J.
    Slee, M.
    McCombe, P.
    Shaw, C.
    Skibina, O.
    Vucic, S.
    Shuey, N.
    Barnett, M.
    Parratt, J.
    Butzkueven, H.
    Jack, D.
    Fabris, J.
    Kalincik, T.
    Jokubaitis, V. G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP64 - NP65
  • [10] Altered erythrocyte MicroRNA profiles in relapsing-remitting multiple sclerosis
    Groen, K.
    Maltby, V. E.
    Tajouri, L.
    Lea, R. A.
    Fink, L.
    Sanders, K. A.
    Scott, R. J.
    Lechner-Scott, J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 582 - 582
12345